Intervention

Interleukin-2

ClinicalTrials.gov intervention label

Clinical trials27

Recruiting9

Common conditions25

Lead sponsors shown15

Clinical trials

27 shown

Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseNCT07192900 · 2026-06-03

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCNCT07255664 · 2025-11-13

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerNCT06532799 · 2024-09-10

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerNCT06532812 · 2024-08-22

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerNCT06538012 · 2024-08-20

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT06121557 · 2023-11-01

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT06121570 · 2023-11-01

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT05981014 · 2023-08-01

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT05981001 · 2023-08-01

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsNCT06237881 · 2024-01-31

ACTIVE_NOT_RECRUITING

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)NCT05798546 · 2022-09-28

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020NCT05385705 · 2022-05-11

Phase II Clinical Trial of Interleukin-2 in ADNCT06096090 · 2022-01-01

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesNCT03546426 · 2019-12-12

ACTIVE_NOT_RECRUITING

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma PatientsNCT02414945 · 2015-05-15

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerNCT01105650 · 2010-07-01

Novel Interventions in HIV-1 InfectionNCT01130376 · 2009-09-01

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast CancerNCT00376805 · 2006-04-01

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)NCT00120185 · 2003-12-01

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 StudiesNCT00311688 · 2003-12-01

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIVNCT00056797 · 2002-03-01

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2NCT00050726 · 2001-05-01

Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive ChemotherapyNCT00001440 · 1995-07-01

Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive PatientsNCT00001474 · 1995-05-01

Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study ModificationsNCT00001409 · 1994-09-01

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected PatientsNCT00001357 · 1993-08-01

Common conditions

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)6 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4 Essen Biotech3 Masonic Cancer Center, University of Minnesota2 BGI, China1 CuraCell TX AB1 David Bartlett, MD1 French National Agency for Research on AIDS and Viral Hepatitis1 Imperial College London1 Indapta Therapeutics, INC.1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 M.D. Anderson Cancer Center1 National Cancer Institute (NCI)1 The Methodist Hospital Research Institute1 University Health Network, Toronto1

Trial status mix

COMPLETED10

RECRUITING9

TERMINATED3

ACTIVE_NOT_RECRUITING2

UNKNOWN2

SUSPENDED1

Phase mix

PHASE118

PHASE216

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.